Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
ApexOnco Front Page
Recent articles
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
The company buys in a PI3Kα and mTOR combo.
Gilead opting against IDE397 is still good news for Ideaya.
Progression-free and overall survival data from Companion-002 are due this quarter.
JSKN027 will become the first ADC with this mechanism to enter human trials.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
A binary Xpovio catalyst is set for March.
